OBJECTIVES: Historically, surgical resection has been the mainstay of treatment for T1N0 oesophageal cancer (OC). More recently, oesophageal sparing endoscopic techniques have shown value for local control in a large institutional series. However, the effect of their utilization upon survival rates in large population series is largely unknown.
INTRODUCTION
The prognosis for patients with T1N0 oesophageal cancer (OC) is significantly better than that for patients with deeper tumours (T2-T4), who are much more likely to develop lymph node metastases and systemic disease. As such, local treatment strategies remain the cornerstone of treatment for T1N0 OC. In the previous 2 decades, local treatment predominantly consisted of oesophagectomy, an operation that historically carries significant morbidity and relatively high rates of surgical mortality [1, 2] . Encouragingly, as surgical techniques and perioperative care have improved, the utilization of surgery has increased and surgical morbidity and mortality have steadily decreased [3] . However, endoscopic methods of resection, including endoscopic mucosal resection and endoscopic submucosal dissection, have also gained traction for T1N0 OC. Several large studies have reported endoscopic techniques to be safe with good long-term cancerrelated outcomes in carefully selected patients. We sought to identify treatment patterns over time for patients with T1N0 OC and to determine whether the choice of treatment influenced survival outcomes.
PATIENTS AND METHODS

The surveillance, epidemiology, and end results database
The surveillance, epidemiology, and end results (SEER) database, maintained by the National Cancer Institute (NCI) since 1973, currently collects data from 18 population-based cancer registries that cover approximately 28% of the US population [4] . Data routinely collected include demographics (age, gender and race), tumour characteristics (site, tumour size, tumour extension, histology and grade), staging information, treatment modalities and survival data. The National Center for Health Statistics provides mortality information of patients included in the SEER database.
Patient population and data collection
This study included all patients, aged 18 years and older, who had local treatment for T1N0M0 OC between 1988 and 2013 in the SEER database (9, 13 and 18 registries; ICD-O-3 site code: 150-159). Derived AJCC-7 staging categories (DAJCCT, DAJCCN and DAJCCM) and extent of disease extension (EOD10_EX) variables were used to identify patients with T1N0M0 OC. Patients who underwent surgery, radiation therapy, local excision or destruction were identified using relevant procedure codes. Patients were excluded from the study if they received multiple treatment modalities or if the primary treatment modality was unspecified. For staging, pathological data were utilized when available, but for patients treated by non-resectional methods, clinical staging was utilized.
In the whole cohort, complete data were available for all the variables studied except for tumour grade and tumour size. The number of patients for whom analysis was done is mentioned in the tables.
Study design
The primary objective of this study was to identify treatment trends for T1N0M0 OC over 25 years in the SEER database. The secondary objective was to assess whether any differences exist in clinicopathological variables or survival in patients undergoing different treatment modalities. To assess utilization trends of the different treatment modalities, the study period was divided into 5 groups by 5-year increments.
Statistical analysis
In the whole cohort, categorical variables were compared by the Pearson's v 2 test and were expressed as number and percentage. Continuous variables were compared by the Mann-Whitney U-or the Kruskal-Wallis H-test and were expressed as median and interquartile range.
For the propensity score-matched data analysis, we used tests that account for the paired nature of the used data. McNemar test was used to assess statistical differences in the categorical variables between the 2 groups, and the paired t-test was used to assess for differences in the continuous variables.
All P-values were 2-sided with statistical significance evaluated at the 0.05 alpha level. Data analysis was performed using the IBM SPSS software (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, version 22.0. IBM Corp.: Armonk, NY, USA) and PSmatching package version 3.04.
Trends analysis. To assess the trends for using the different treatment modalities over the study period (divided into 5 time intervals), the Mantel-Haenszel test for trend in the crosstab function was used. A statistically significant trend was considered if the P-value of the Linear-by-Linear Association was < _0.05.
Survival analysis. Only patients with first primary tumour and complete dates of follow-up were included in the overall survival (OS) analysis of the whole cohort (n = 3858). For the cancer-specific survival (CSS), only patients with first primary tumour, complete dates of follow-up and known cause of death were included in the analysis (n = 3780). First primary tumour, complete dates of follow-up, deaths from any cause, deaths from OCs and survival time were identified using the following variables: first malignant primary indicator 'FRSTPM', vital status recode 'STAT_REC', SEER cause-specific death classification 'VSRTSADX', cause of death to SEER site recode 'CODPUB', SEER other causes of death classification 'ODTHCLASS', survival month flag 'srv_time_mon_flag' and survival months 'srv_time_mon'.
The propensity score analysis was performed [surgery versus local therapy and surgery versus radiotherapy (RT)] controlling for age, gender, tumour size, histology, grade and year of diagnosis (logistic regression algorithm, nearest neighbour, 1:1, matching with no replacement, caliper 0.05). Only patients with first primary tumour, complete dates of follow-up and complete data on all the matching variables were included in the analysis (n = 3780).
OS and CSS for the whole cohort and propensity-matched groups were estimated using the Kaplan-Meier method. Differences in survival were compared using the log-rank test for the whole cohort and the stratified log-rank test for the propensity-matched groups (stratified by matched pairs) [5] . The Cox proportional hazard multivariable model was constructed to assess the independent predictors of cancer-specific mortality for the whole cohort.
RESULTS
Study population
In the study period , 80 900 patients were diagnosed with OC in the SEER database. Of them, 8651 had documented T1N0M0 stage. The final analysis was performed on 5497 patients after excluding patients who had multiple treatment modalities and those in whom treatment modality could not be specified.
Demographics and tumour characteristics
Median age of the patients included in the study was 69 years (interquartile range 61-77), and 4285 (78%) patients were men. The majority of the patients had tumours located in the lower third/abdominal oesophagus (n = 3363, 61%). Median tumour size was 2 cm (interquartile range 1-4). Adenocarcinoma was the most common histology (n = 3404, 62%), whereas 1642 (30%) patients had squamous cell carcinoma. Information on tumour grade was present for 4194 patients, of which 1566 (37%) patients had Grade III/IV tumours. Patient demographics and tumour characteristics are summarized in Table 1 .
Treatment modalities
Oesophagectomy was performed in 2262 (41.1%) patients, in whom the median number of lymph nodes removed was 5 (1-10). Local excision was performed in 791 (14%) patients, and local destruction was done in 106 (2%) patients. Radiation therapy (potentially with chemotherapy, a variable not included in the SEER database) was the treatment modality in 2338 (42.5%) patients. Of these, 2228 (95%) patients received beam radiation, 14 (0.6%) patients had radioisotopes/radioactive implants and 24 (1%) patients had both beam radiation and radioisotopes/radioactive implants. The different treatment techniques used are summarized in Table 1 .
Clinicopathological differences and trends in different treatment modalities
The clinicopathological characteristics of patients undergoing different treatment modalities are summarized in Table 2 . Patients who underwent surgery were younger and more often male. Patients treated with local therapy, including endoscopic approaches, had smaller tumour sizes and lower grade tumours. Finally, patients treated with radiation therapy were older, had longer and higher grade tumours and more likely had squamous cell carcinoma. In the most recent time period , the use of surgical resection declined by almost half (61-34%), local excision/destruction increased 6-fold (4-25%) and the use of radiation therapy slightly increased (35-41%), when compared with the earlier time period (1988-92). The ratio of surgery to endoscopic treatment declined from 15:1 in the earliest time period to 1.4:1 in the most recent time period (Fig. 1A) . A statistically significant trend was confirmed with the Mantel-Haenszel test for trend in the crosstab function. The P-value of the Linear-byLinear Association was <0.001.
A subgroup analysis was done for patients in whom T1 subclassification (T1a/T1b) could be identified using the AJCC, 7th edition-T stage and Extent of disease variables (T1a, n = 1445-T1b, n = 928). Interestingly, in the most recent time period group (2008-13), endoscopic treatment was performed more frequently compared with surgery for T1a tumours but not for T1b tumours (surgery to endoscopic treatment ratio of 1:1.6 for T1a, when compared with 3:1 for T1b tumours) (Fig. 1B and C) .
Survival analysis
In the whole cohort, there was no statistically significant difference in OS between patients undergoing oesophagectomy and local therapy ( Fig. 2A , 5-year OS: 67% vs 59%; P = 0.074). However, patients treated with RT had significantly worse OS compared with either oesophagectomy or local therapy (5-year OS: 15%; P < 0.001). Local therapy had a better CSS compared with oesophagectomy (5-year CSS: 83% vs 77%; P = 0.017), and RT had worse CSS compared with either surgery or local therapy (5-year CSS: 24%; P < 0.001) (Fig. 2B) .
There was no difference in OS (5-year OS: 60% vs 53%; P = 0.112) or CSS (5-year CSS: 85% vs 74%; P = 0.693) between patients undergoing local excision and those treated with local destruction.
A subgroup analysis based on the histological subtypes was done. In patients who had adenocarcinoma, local therapy had better 5-year CSS compared with oesophagectomy (85% vs 79%; P = 0.042), and oesophagectomy had better 5-year CSS compared with RT (79% vs 22%; P < 0.001). In patients who had squamous cell carcinoma, no significant difference in 5-year CSS was found between oesophagectomy and local therapy (65% vs 74%; P = 0.697), and oesophagectomy had better 5-year CSS compared with RT (65% vs 25%. P < 0.001).
Among patients who had RT, no difference in 5-year CSS was found between those who had adenocarcinoma and those who had squamous cell carcinoma (22% vs 25%; P = 0.865).
In a subgroup analysis of patients in whom T subclassification could be identified, no statistically significant difference in OS was observed between patients undergoing oesophagectomy and local therapy in either T1a or T1b tumours (5-year OS-T1a: 71% vs 64%, P = 0.512; T1b: 59% vs 53%, P = 0.609). Similarly, there was no statistical difference in CSS between oesophagectomy and local therapy in patients who had either T1a or T1b (5-year CSST1a: 81% vs 86%, P = 0.114; T1b: 70% vs 72%, P = 0.353). RT consistently had worse OS and CSS in T1a and T1b compared with either oesophagectomy or local therapy (P < 0.001) (Fig. 3A-D) .
The propensity score-matching analysis was done between patients undergoing oesophagectomy and local therapy (n = 216 in each group), and between oesophagectomy and RT (n = 497 in each group) ( Table 3 ). There was no difference in OS (5-year OS: 59% vs 61%, P = 0.579) and CSS (5-year CSS: 81% vs 89%; P = 0.257) between patients undergoing oesophagectomy and local therapy (Fig. 4A ). However, oesophagectomy had superior 5-year CSS compared with radiation alone (Fig. 4B , 73% vs 38%; P < 0.001).
The aforementioned survival analyses were performed on patients with complete follow-up data. To confirm these results, we repeated all survival analyses to include all patients (with and without complete follow-up data). No differences were noted between our original and repeated survival analyses (Supplementary Material, Table S1 ).
The multivariable Cox regression analysis was performed for the whole cohort. Independent predictors of cancer-specific mortality were advanced age [hazard ratio (HR) 1.02, 95% confidence interval (CI) 1.02-1.03; P < 0.001], larger tumour size (HR 1.005, 95% CI 1.003-1.008; P < 0.001), RT as treatment modality (HR 3.67, 95% CI 3.03-4.44; P < 0.001), Grade III/IV tumours (HR 1.25, 95% CI 1.07-1.46; P = 0.004) and earlier year of diagnosis (1988-92) (HR 1.75, 95% CI 1.21-2.53; P = 0.003) ( Table 4 ). 
DISCUSSION
The treatment options for patients with T1N0 OC have changed dramatically over the past 25 years. Most patients clinically staged as T1N0 can be expected to have low rates of lymph node metastases and disseminated disease [6, 7] . As such, local treatment therapies are preferable. This historically consisted of either surgical resection or radiation therapy. However, both these treatment modalities have the potential for significant treatmentrelated morbidity or mortality. This is particularly true for oesophagectomy, for which in-hospital and 30-day mortality rates were reported to be between 6.1% and 13.1% in large cohorts of patients between the 1990s and 2000s. Encouragingly, as surgical techniques and perioperative care have improved, the utilization of surgery has increased, and surgical morbidity and mortality have steadily decreased [3] . In the most recent analysis of the Society of Thoracic Surgeons General Thoracic Surgery Database for oesophagectomy (2012-14), major complications occurred in 33.1% of patients, and perioperative mortality occurred in only 3.1% of patients. However, it has been suggested that such specialized databases are not representative of national results, in which mortality has been shown to be higher [8] .
Given the morbidity and the potential mortality of oesophagectomy, efforts have been undertaken to develop methods of endoscopic treatment for T1N0 OC. Early methods, such as photodynamic and laser-based therapies, yielded disappointing results. However, endoscopic resection techniques, including endoscopic mucosal resection and endoscopic submucosal dissection, were subsequently developed. Such techniques were initially controversial, and evidence with regard to their effectiveness varied [9] [10] [11] [12] . Concerns were raised over the potential for misclassification of tumour depth and over the inability of accurate lymph node staging, both possibly contributing to showed that the use of endoscopic resection/ablation techniques was steadily increasing [13, 14] . These analyses reported different effects of endoscopic therapy on survival, with beneficial effects regarding CSS (HR 0.46, 95% CI 0.27-0.77) in the SEER database and detrimental effects to conditional 5-year survival (HR 1.63, 95% CI 1.07-2.47) in the National Cancer Database. Nevertheless, in 2012, the NCCN guidelines endorsed endoscopic resection/ablation as the 'preferred' method of management for T1aN0 OC, although the NCCN continued to recommend surgery for T1bN0 OC. We sought to perform a modern analysis of treatment patterns for patients with T1N0 OC, expecting to observe a continued increase in the utilization of endoscopic techniques. We sought to compare OS and CSS in these cohorts including patients through 2013 in which both surgical and endoscopic techniques can be expected to have improved. Furthermore, we were particularly interested to determine whether endoscopic techniques were being utilized more frequently for patients with T1b tumours, who have been shown to be at higher risk for lymph node metastases, up to 18% in recent analysis of the SEER database [7] .
In our study, we observed a dramatic increase in the utilization of endoscopic treatment, particularly apparent in the most recent In that final time period, the use of endoscopic treatment also increased markedly for T1b tumours, of which 25% of those treated without radiation were treated endoscopically (compared with just 4% in the period from 1988 to 2007). Appropriately, endoscopic techniques appear to have been more commonly utilized in older patients with smaller, lower grade tumours when compared with patients who underwent surgery. We did not evaluate trends in patients selected for endoscopic therapy over time, but expect that it is increasingly being used in higher risk patients.
Given the markedly increased use of endoscopic treatment for T1N0 OC, we thought it is important to evaluate whether such treatment affects cancer-related survival outcomes. In the cohort as a whole, we observed a slight improvement in CSS at 5 years following endoscopic therapy versus oesophagectomy (83% vs 77%; P = 0.017). This is not surprising given the smaller, lower grade tumours in that cohort which were more likely to be T1a. In a separate analysis of patients with T1a and T1b tumours, we found no differences in CSS between endoscopic therapy and oesophagectomy. Furthermore, to provide balanced patient cohorts to better evaluate treatment effects, we performed propensity matching of endoscopic and surgical patients (n = 216 each). In these groups, after adjusting for patient age and gender, tumour size, histology and grade and for year of diagnosis, we observed that endoscopic therapy and oesophagectomy are equivalent treatment options.
It is important to also compare and evaluate both surgical and endoscopic treatments against radiation therapy. Despite decreases in surgical morbidity and mortality and the widespread adoption of endoscopic therapy, it is notable that even between 2008-13, most T1N0 patients are treated with radiation therapy. The rationale for this is not obvious, although radiation tended to be given to older patients, with larger, higher grade tumours, particularly those with squamous cell carcinoma. The SEER database does not clarify whether radiation was given alone or in conjunction with chemotherapy, although combining modalities would likely be the standard approach in the more recent time periods. These patients did markedly worse than patients treated with oesophagectomy or endoscopic therapy, both in terms of OS and CSS. In the multivariable analysis, the use of radiation therapy (compared with oesophagectomy) was the strongest independent predictor of higher cancer-specific mortality (HR 3.669, 95% CI 3.0033-4.438) for T1N0 OC patients. Given that clinical understaging in the radiation group may explain some of the dramatic differences in survival for the cohort as a whole, propensity-matched groups of patients undergoing oesophagectomy and radiation therapy were compared according to demographic and tumour characteristics to better compare the treatment effects. In this matched cohort (n = 497 in each group), we still observed markedly worse outcomes in patients treated with radiation therapy (5-year CSS for oesophagectomy when compared with radiation, 73% vs 38%; P < 0.001). Although the matched cohort cannot account for all treatment allocation biases, these data strongly suggest that T1N0 OC patients should be treated with oesophagectomy or endoscopic therapy as opposed to radiation alone or chemoradiation.
Limitations
Our study has several limitations. The retrospective nature of the SEER database along with the lack of detailed clinical staging information regarding EUS and PET scans may limit the generalizability of the study findings. Additionally, CSS may not be accurately captured in any large database and is susceptible to many assumptions. As such, we urge caution while applying the findings of this study to everyday practice and suggest that careful clinical staging and multidisciplinary care teams should be utilized to guide treatment decisions for patients with presumed early-stage OC. In practice, it is likely that significant bias occurred in the selection of T1a and particularly T1b patients for endoscopic therapy, with the preferential use of endoscopic therapy in tumours judged to be of lower risk. It is also possible that the study was underpowered to detect a difference in survival between these treatment modalities. We would particularly urge caution in using these data to justify endoscopic therapy routinely for T1b tumours, given the higher risk of nodal metastases with these tumours [7] . It is impossible to account for selection bias in our study. It is also notable that in the SEER database, data regarding the utilization of chemotherapy are lacking. It is unclear whether patients treated with radiation alone also received chemotherapy. Detailed descriptions of patient comorbidities are also lacking, which could also affect treatment allocation and OS. This may be particularly true of patients treated with chemoradiation or palliative radiation therapy. Although we tried to account for this by propensity matching, the poor survival in the radiation group may not be reflective of outcomes, which could be obtained in prospective studies of well-balanced patient cohorts. Nevertheless, the broad strengths of the SEER database including its population-based nature, its strict coding variables and its recording of cancer-specific outcomes make it an ideal database for evaluating our question of treatment allocation for patients with T1N0 OC.
CONCLUSION
In this analysis of the SEER cancer registry between 1988 and 2013, a statistically significant marked increase in the use of endoscopic resection techniques for the treatment of T1N0 OC is apparent, particularly between 2008 and 2013. Endoscopic resection is now more commonly performed than oesophagectomy for T1aN0 OC. Its use is increasing for T1bN0 tumours as well. In the cohort studied, no statistically significant difference in CSS between endoscopic resection and oesophagectomy was observed, both of which are markedly superior to treatment with radiation therapy.
SUPPLEMENTARY MATERIAL
Supplementary material is available at EJCTS online.
Conflict of interest: none declared.
